Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
AOD-9604
Metabolic & Weight LossPhase 3Also known as: AOD9604
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond. It reached Phase 3 clinical trials for obesity but was discontinued after failing to demonstrate significant benefit over placebo at the primary endpoint.
Overview
Key Takeaways
- →Fat loss
- →Metabolic improvement
- →Joint repair (proposed)
- →Half-life: ~30–60 minutes
At A Glance
AOD-9604 stimulates lipolysis through the GH receptor's fat-metabolizing domain while inhibiting lipogenesis from glucose, without activating the IGF-1 axis or affecting insulin sensitivity. This selectivity provides targeted fat mobilization. In vitro and animal data also suggest chondrogenic and proteoglycan synthesis properties, leading to its investigation for osteoarthritis (where Phase 2 trials were more favorable).
AOD-9604 stimulates lipolysis through the GH receptor's fat-metabolizing domain while inhibiting lipogenesis from glucose, without activating the IGF-1 axis or affecting insulin sensitivity. This selectivity provides targeted fat mobilization. In vitro and animal data also suggest chondrogenic and proteoglycan synthesis properties, leading to its investigation for osteoarthritis (where Phase 2 trials were more favorable).
Overview
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond. It reached Phase 3 clinical trials for obesity but was discontinued after failing to demonstrate significant benefit over placebo at the primary endpoint. Despite this, research-grade AOD-9604 remains popular for its proposed lipolytic and joint repair properties.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
CAS Number
221231-10-3
Molecular Formula
C78H123N23O23S2
Molecular Mass
1817.1 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Active cancer. Pregnancy or breastfeeding. Limited safety data — use with extreme caution.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$34.99
up to $50.00
$6.9980
2
2
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
AOD-9604 5mg | vial | 1 vial● In Stock | $34.99BEST | $6.998 | ||
| AOD-9604 5mg Vial | vial | 1 vial● In Stock | $50.00 | $10.000 |
Price History
2 data pointsVendors Selling AOD-9604
Related Compounds
View AllCagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).
View Full Dosage Guide →
Protocols, calculator & safety for AOD-9604
Research Score
1 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Limited research available
Quick Facts
Half-Life
~30–60 minutes
Molecular Weight
1817.1 g/mol
Administration
Subcutaneous, Oral
CAS Number
221231-10-3
Trial Phase
Phase 3
Safety Profile
Low RiskCommon Side Effects
- • Mild injection site reactions
- • Headache
- • Nausea (rare)
Stop Use If
- Active malignancy
- Known peptide hormone hypersensitivity
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is AOD-9604 used for in research?
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond. It reached Phase 3 clinical trials for obesity but was discontinued after failing to demonstrate significant benefit over placebo at the primary endpoint. Despite this, research-grade AOD-9604 remains popular for its proposed lipolytic and joint repair properties.
What forms does AOD-9604 come in?
AOD-9604 is available in vial form.
How much does AOD-9604 cost?
Prices start at $34.99 across 2 verified vendors.
How do I compare AOD-9604 vendors?
Compare prices, payment methods, shipping, and COA scores across 2 vendors.
Research Tools
Related Compounds
View AllCagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Tirzepatide
Metabolic & Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).